Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort
Phase of Trial: Phase IV
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 17 May 2010 Actual patient number (270) added as reported by ClinicalTrials.gov.
- 17 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Feb 2010 New trial record